Azide-PEG3-C1-Ala is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.
Nutlin-C1-amido-PEG4-C2-N3 is a novel compound that functions as a ligand-linker conjugate for the E3 ligase. It is a synthesized molecule incorporating the MDM2 ligand derived from Nutlin 3, and a 4-unit PEG linker. This compound is specifically designed for utilization in PROTAC technology.
Estrone-N-O-C1-amido (ERα ligand 1) is an estrogen ligand derived from Estrone that specifically binds to estrogen receptor α (ERα). Through a linker, Estrone-N-O-C1-amido (ERα ligand 1) forms a complex with the cIAP1 ligand Bestatin, leading to the creation of SNIPER[1].
Propargyl-O-C1-amido-PEG2-C2-NHS ester is a non-cleavable 2-unit PEG linker employed in antibody-drug conjugation (ADC) to connect antibodies with drugs.
Propargyl-O-C1-amido-PEG4-C2-NHS ester is a non-cleavable 4-unit PEG linker employed in antibody-drug conjugation (ADC) to connect antibodies with drugs.
Propargyl-O-C1-amido-PEG3-C2-NHS ester is a non-cleavable 3-unit polyethylene glycol (PEG) linker employed for the chemical synthesis of antibody-drug conjugates (ADCs).
JTK-853 is a novel, non-nucleoside inhibitor of Hepatitis C Virus (HCV) polymerase. It also displays effective antiviral activity in HCV replicon cells (EC50s: 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively).
GSK-625433, a homochiral inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase, has the ability to inhibit the polymerase of both HCV genotypes 1a and 1b.
Tpl2 kinase inhibitor is an inhibitor of tumor progression locus 2 (Tpl2; IC50= 0.05 μM).1It is selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 μM, respectively). Tpl2 kinase inhibitor inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 μM, respectively). It enhances differentiation induced by calcitriol in HL-60 and U937 leukemia cells when used at a concentration of 5 μM.2Tpl2 kinase inhibitor (5 μM) inhibits the proliferation of KG-1a leukemia cells.3 1.Garvin, L.K., Green, N., Hu, Y., et al.Inhibition of Tpl2 kinase and TNF-α production with 1,7-naphthyridine-3-carbonitriles: Synthesis and structure-activity relationshipsBioor. Med. Chem. Lett.15(23)5288-5292(2005) 2.Wang, X., and Studzinski, G.P.Expression of MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D3 in parallel with activated c-jun during differentiation of human myeloid leukemia cellsJ. Steroid. Biochem. Mol. Biol.121(1-2)395-398(2010) 3.Wang, X., Gocek, E., Novik, V., et al.Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D3Cell Cycle9(22)4542-4551(2010)
STING agonist 1a is an agonist of stimulator of interferon genes (STING).1It induces expression of an IRF-inducible SEAP reporter gene in a cell-based assay (EC50= 16.77 μM). STING agonist 1a (12.5-100 μM) induces expression of IFN-β, IL-6, and chemokine (C-X-C motif) ligand 10 (CXCL10) in THP-1 cells, an effect that can be reversed by STING knockout or the STING inhibitor H-151 . 1.Hou, H., Yang, R., Liu, X., et al.Discovery of triazoloquinoxaline as novel STING agonists via structure-based virtual screeningBioorg. Chem.100103958(2020)